FENC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fennec Pharmaceuticals is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 available. The stock has some bullish long-term fundamentals from Pedmark/Pedmarqsi growth, but the current setup is mixed: technicals are only neutral-to-slightly positive, option positioning is extremely call-heavy but with no trading volume, and the stock is trading near a short-term pivot with downside implied by pattern analysis. I would not buy aggressively at the current pre-market price of 6.9; I would hold and wait for confirmation after earnings or a cleaner breakout above resistance.
Current pre-market price is 6.9, sitting just above the pivot at 6.701 and below first resistance at 7.133. MACD histogram is positive at 0.0807 but contracting, which suggests momentum is weakening rather than accelerating. RSI_6 at 57.914 is neutral, so the stock is not overbought or oversold. Moving averages are converging, indicating a trend that is not strongly established. Overall, the short-term technical picture is neutral with mild upward bias, but not enough to call it an attractive immediate long-term entry.
["B. Riley initiated coverage with a Buy rating and $16 price target.", "Analyst expects roughly 55% annual revenue growth through 2027.", "Pedmark is described as the first and only FDA-approved therapy for cisplatin-induced hearing loss.", "No approved competitors and limited pipeline threats were highlighted by analysts.", "Q4 2025 revenue grew 73.84% YoY, showing strong top-line momentum.", "Upcoming Q1 2026 results and conference call could provide an event-driven catalyst."]
["The stock has a negative near-term pattern profile, with projected weakness over the next week and month.", "Net income remains negative at -4.787 million, so the company is still unprofitable.", "EPS is still negative at -0.15.", "Gross margin declined year over year to 87.2.", "Hedge funds and insiders are both neutral, with no notable accumulation signal.", "No recent congress trading data is available.", "No AI Stock Picker or SwingMax signal is present today."]
Latest quarter provided is Q4 2025. Revenue increased to 13.777 million, up 73.84% year over year, which is strong and shows accelerating commercial growth. However, profitability remains weak: net income was -4.787 million and EPS was -0.15, both still negative, though improved year over year. Gross margin remains high at 87.2%, but it declined 4.76% year over year. The latest quarter shows strong growth but not yet consistent earnings power.
Recent analyst sentiment is bullish. On 2026-02-12, B. Riley initiated coverage with a Buy rating and a $16 price target, arguing the market is materially undervaluing Pedmark's commercial runway. The firm also emphasized the absence of approved competitors and projected strong revenue growth through 2027. Wall Street pros are positive on the growth story and niche monopoly-like positioning, while the main con is that the company is still loss-making and the stock's short-term price action is not showing strong confirmation.
